{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:21:25Z","timestamp":1792304485192,"version":"4.4.0"},"reference-count":108,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p>Previous clinical studies have shown heterogeneity in individual patient responses to antiplatelet therapy and high residual platelet reactivity is associated with increased risk of adverse clinical events. Monitoring response to antiplatelet therapy and tailoring treatment accordingly is currently not recommended in routine clinical practice largely due to the lack of a standardized definition of antiplatelet therapy hyporesponse and the need for a widely accepted point\u2010of\u2010care platelet function test that can be reliably utilized in frontline clinical practice. Recent data have shown that titrating the dose of clopidogrel in patients undergoing percutaneous coronary intervention significantly reduces the incidence of major adverse cardiovascular events and large\u2010scale clinical trials are currently underway to investigate whether individually tailored treatment based on results of platelet function testing leads to improved clinical outcome. Furthermore, genetic testing has demonstrated a link between CYP2C19 genetic polymorphisms, altered clopidogrel metabolite concentrations and adverse clinical events. Clinical studies are currently underway to investigate the potential clinical benefit associated with genotype\u2010guided tailoring of antiplatelet therapy. With the advent of newer, more potent antiplatelet agents and their associated increased bleeding risks, it will become imperative in the future to select the most appropriate, safe and effective drug.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2011.03955.x","type":"journal-article","created":{"date-parts":[[2011,3,2]],"date-time":"2011-03-02T15:18:49Z","timestamp":1299079129000},"page":"683-696","source":"Crossref","is-referenced-by-count":57,"title":["Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations"],"prefix":"10.1111","volume":"72","author":[{"given":"Nalyaka","family":"Sambu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Curzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,9]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-06-0418"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39430.529549.BE"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.04.014"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.08.058"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.12.044"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.08.048"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.041"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.06.065"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl275"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03458.x"},{"key":"e_1_2_10_12_2","first-page":"44","article-title":"Evaluation of electrical aggregometry: comparison with optical aggregometry, secretion of ATP, and accumulation of radiolabeled platelets","volume":"101","author":"Ingerman\u2010Wojenski C","year":"1983","journal-title":"J Lab Clin Med"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0160-5402(80)90024-8"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614344"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-12-0832"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.181"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm226"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.5.620"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2006.28.5.990205"},{"key":"e_1_2_10_20_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1160\/TH07-09-0575","article-title":"The use of the VerifyNow P2Y12 pointof\u2010care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration","volume":"99","author":"Jakubowsky JA","year":"2008","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02187.x"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.034"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn046"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.812636"},{"key":"e_1_2_10_25_2","unstructured":"Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation and Interruption Versus Continuation of Double Antiplatelet Therapy (ARCTIC). Available athttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00827411?term=ARCTIC&rank=2(last accessed 23 March 2011)."},{"key":"e_1_2_10_26_2","unstructured":"Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER\u2010PCI). Available athttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00910299?term=TRIGGER+PCI&rank=1(last accessed 23 March 2011)."},{"key":"e_1_2_10_27_2","unstructured":"Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition (DANTE). Available athttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00774475?term=DANTE&rank=1(last accessed 23 March 2011)."},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/09537100701329162"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/09537100600757521"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/09537100600935259"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/17482940701385203"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.05.090"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lab.2004.01.011"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.10.050"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.05.034"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00156.x"},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2009.00106.x"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-05-0242"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-09-0577"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-07-0478"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPTE3K1SGAPOIZ"},{"key":"e_1_2_10_42_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-05-0284"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03699.x"},{"key":"e_1_2_10_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.02.025"},{"key":"e_1_2_10_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03709.x"},{"key":"e_1_2_10_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(02)00405-X"},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.3.329"},{"key":"e_1_2_10_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02656.x"},{"key":"e_1_2_10_49_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2004.047050"},{"key":"e_1_2_10_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.05.001"},{"key":"e_1_2_10_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02897.x"},{"key":"e_1_2_10_52_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-08-0530"},{"key":"e_1_2_10_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256290"},{"key":"e_1_2_10_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2008.10.046"},{"key":"e_1_2_10_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.04.047"},{"key":"e_1_2_10_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.047"},{"key":"e_1_2_10_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb07467.x"},{"key":"e_1_2_10_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90516-4"},{"key":"e_1_2_10_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)00308-5"},{"key":"e_1_2_10_60_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.38.1.97"},{"key":"e_1_2_10_61_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.112202999"},{"key":"e_1_2_10_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2010.05.014"},{"key":"e_1_2_10_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02387.x"},{"key":"e_1_2_10_64_2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1160\/TH08-01-0002","article-title":"Relationship between high platelet turnover and platelet function in high risk patients with coronary artery disease on dual antiplatelet therapy","volume":"99","author":"Cesari F","year":"2008","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.051"},{"key":"e_1_2_10_66_2","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1160\/TH09-04-0215","article-title":"Utility of 96\u2010well plate aggregometry and measurement of thrombin adhesion to determine aspirin and clopidogrel effectiveness","volume":"102","author":"Armstrong PC","year":"2009","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_67_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.596627"},{"key":"e_1_2_10_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03714.x"},{"key":"e_1_2_10_69_2","doi-asserted-by":"publisher","DOI":"10.1080\/09537100903003227"},{"key":"e_1_2_10_70_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1160\/TH06-12-0722","article-title":"The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin","volume":"98","author":"Dropinsky J","year":"2007","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_71_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.15.1593"},{"key":"e_1_2_10_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.10.040"},{"key":"e_1_2_10_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.01.034"},{"key":"e_1_2_10_74_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1232"},{"key":"e_1_2_10_75_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1657677"},{"key":"e_1_2_10_76_2","doi-asserted-by":"publisher","DOI":"10.1080\/0953710021000057866"},{"key":"e_1_2_10_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2008.9"},{"key":"e_1_2_10_78_2","doi-asserted-by":"publisher","DOI":"10.1159\/000315147"},{"key":"e_1_2_10_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(93)90164-J"},{"key":"e_1_2_10_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)03014-0"},{"key":"e_1_2_10_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.10.021"},{"key":"e_1_2_10_82_2","first-page":"2222","article-title":"The Results of the ASCET Trial. 2010 clinical trial\/clinical science abstracts","volume":"122","author":"Pettersen AA","year":"2010","journal-title":"Circulation"},{"key":"e_1_2_10_83_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.170815"},{"key":"e_1_2_10_84_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.833236"},{"key":"e_1_2_10_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2008.08.018"},{"key":"e_1_2_10_86_2","first-page":"2218","article-title":"Standard versus high\u2010dose clopidogrel according to platelet function testing after PCI: results of the GRAVITAS Trial. 2010 clinical trial\/clinical science abstracts","volume":"122","author":"Price MJ","year":"2010","journal-title":"Circulation"},{"key":"e_1_2_10_87_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029132"},{"key":"e_1_2_10_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808227"},{"key":"e_1_2_10_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61845-0"},{"key":"e_1_2_10_90_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"e_1_2_10_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp041"},{"key":"e_1_2_10_92_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.885194"},{"key":"e_1_2_10_93_2","unstructured":"Food and Drug Administration drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug(safety announcement).2010. Available at:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm203888.htm#sa(last accessed 23 March 2011)."},{"key":"e_1_2_10_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.05.013"},{"key":"e_1_2_10_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.029"},{"key":"e_1_2_10_96_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008410"},{"key":"e_1_2_10_97_2","unstructured":"Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study (GeCCO). Available athttp:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00995514?term=GeCCO&rank=1(last accessed 23 March 2011)."},{"key":"e_1_2_10_98_2","unstructured":"Adjunctive Cilostazol Versus High Maintenance\u2010dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism (ACCELAMI2C19). Available athttp:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00915733?term=ACCELAMI2C19&rank=1(last accessed 23 March 2011)."},{"key":"e_1_2_10_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.07.004"},{"key":"e_1_2_10_100_2","doi-asserted-by":"publisher","DOI":"10.4244\/51"},{"key":"e_1_2_10_101_2","doi-asserted-by":"publisher","DOI":"10.1177\/1074248407304731"},{"key":"e_1_2_10_102_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_2_10_103_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.919456"},{"key":"e_1_2_10_104_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_2_10_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.06.038"},{"key":"e_1_2_10_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.02.054"},{"key":"e_1_2_10_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.06.013"},{"key":"e_1_2_10_108_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-8952-4"},{"key":"e_1_2_10_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.05.041"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2011.03955.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2011.03955.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T13:13:53Z","timestamp":1694610833000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2011.03955.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,9]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1365-2125.2011.03955.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03955.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,9]]}}}